Earnings Preview: What To Expect From Bristol-Myers Squibb's Report
Valued at a market cap of $113.1 billion, Bristol-Myers Squibb Company (BMY) is a leading global biopharmaceutical company focused on developing innovative treatments for serious diseases, including cancer,
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Bristol Myers Squibb (BMY) has been one of the most searched ... Over the past month, shares of this biopharmaceutical company have returned -0.9%, compared to the Zacks S&P 500 composite's ...
Bristol-Myers Squibb Co (BMY) Stock Posted a Gross Margin of 55.87% Over the Past Year: Is This Justifiable?
Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the stock to Neutral,
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
Bristol Myers Squibb (BMY) ended the recent trading session at $56.29, demonstrating a -0.16% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 1%.
Wedmont Private Capital Has $586,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)
Wedmont Private Capital grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 29.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors
Shares of Bristol Myers Squibb Co. BMY slumped 0.84% to $55.36 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.16% to 5,836.
FiercePharma3d
JPM25: BMS, Pfizer and Merck CEOs address key patent cliffs and plans to replace sales
Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.
NBC Connecticut4d
Bristol Myers Squibb CEO describes new drug for treating schizophrenia
Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenfy, which can be used to treat psychiatric ...
Positive Outlook for Bristol-Myers Squibb with Promising Market Access and Societal Benefits of Cobenfy
Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...
CSR Wire4d
Bristol Myers Squibb Named to Dow Jones Sustainability Index North America for Second Consecutive Year
Bristol Myers Squibb announced that it has been named in the prestigious Dow Jones Sustainability Index (DJSI) for the second ...
Seeking Alpha3d
BMY Bristol-Myers Squibb Company
View Bristol-Myers Squibb Company (BMY) current and estimated P/E ratio data provided by Seeking Alpha.
ArsenalBios Says Bristol Myers Squibb Exercises Exclusive License Option For AB-4000 Series Programs
Arsenal Biosciences, Inc., a clinical-stage programmable cell therapy company, announced Monday that drug maker Bristol-Myers Squibb ...